

---

**1. IDENTIFICATION**

---

<b>Product Name</b>	EQUIMAX® (ivermectin 1.87%/praziquantel 14.03%) Paste
<b>Recommended use of the chemical and restrictions on use</b>	
<b>Identified uses</b>	Worm control for horses and ponies
<b>Restrictions on Use</b>	Not for human use.
<b>Company Identification</b>	Virbac AH, Inc. P.O. Box 162059 Fort Worth, Texas 76161
<b>Customer Information Number</b>	(800) 338-3659
<b>Emergency Telephone Number</b>	
<b>Chemtrec Number</b>	(800) 424-9300
<b>Other Emergency Number:</b>	Poison Control Center: 1-800-222-1222 (human) HOT LINE NUMBER: 1-800-345-4735 (human and pet)
<b>Issue Date</b>	December 21, 2015
<b>Supersedes Date</b>	November 9, 2011

*Safety Data Sheet prepared in accordance with OSHA's Hazard Communication Standard (29 CFR 1910.1200) and the Globally Harmonized System of Classification and Labelling of Chemicals (GHS)*

---

**2. HAZARDS IDENTIFICATION**

---

**Hazard Classification**

Acute Hazards to the Aquatic Environment – Category 1 (This classification not adopted by OSHA.)

**Label Elements**

Hazard Symbols



Signal Word: Warning

**Hazard Statements**

Very toxic to aquatic life.

**Precautionary Statements****Prevention**

Avoid release to the environment.

**Response**

None

**Storage**

None

**Disposal**

Dispose of contents/container in accordance with local regulation.

---

**2. HAZARDS IDENTIFICATION**

---

**Other Hazards**

None

**Specific Concentration Limits**

The values listed below represent the percentages of ingredients of unknown toxicity.

Acute oral toxicity	0%
Acute dermal toxicity	<10%
Acute inhalation toxicity	<10%
Acute aquatic toxicity	10 - 20%

---

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

---

**Synonyms:**

This product is a mixture.

<b>Component Name</b>	<b>CAS Number</b>	<b>Concentration</b>
Praziquantel	55268-74-1	14.03%
Ivermectin	70288-86-7	1.87%
Titanium Dioxide	13463-67-7	1 - 5%

---

**4. FIRST AID MEASURES**

---

**Description of necessary first-aid measures****Eyes**

Immediately flood the eye with plenty of water for at least 15-20 minutes, holding the eye open. Obtain medical attention if soreness or redness persists.

**Skin**

Wash skin thoroughly with soap and water. Obtain medical attention if redness or soreness persists.

**Ingestion**

Call a poison control center or doctor immediately for treatment advice. Do not induce vomiting unless told to do so by a poison control center or doctor. Do not give anything by mouth to an unconscious person.

**Inhalation**

Remove person to fresh air. Seek medical attention if symptoms persist.

**Most important symptoms/effects, acute and delayed**

Aside from the information found under Description of necessary first aid measures (above) and Indication of immediate medical attention and special treatment needed, no additional symptoms and effects are anticipated.

**Indication of immediate medical attention and special treatment needed****Notes to Physicians**

Treat symptomatically.

---

**5. FIRE - FIGHTING MEASURES**

---

**Extinguishing Media**

Use extinguishing media appropriate for surrounding materials.

---

**5. FIRE - FIGHTING MEASURES**

---

**Unusual Fire and Explosion Hazards**

Can release hazardous vapors during a fire.

**Protective Equipment for Fire-Fighting**

Wear full protective clothing and self-contained breathing apparatus.

---

**6. ACCIDENTAL RELEASE MEASURES**

---

**Personal precautions, protective equipment and emergency procedures**

Wear appropriate protective clothing.

**Environmental Precautions**

Prevent the material from entering drains or watercourses.

**Methods and materials for containment and cleaning up**

Wipe up and transfer into suitable containers for recovery or disposal.

---

**7. HANDLING AND STORAGE**

---

**Precautions for safe handling**

Wear appropriate protective clothing. Wash hands after dispensing to dog and before eating, drinking or smoking.

**Conditions for safe storage**

Store in original container at room temperature 25°C/77°F with excursions permitted between 59°F and 86°F (15°C - 30° C). Keep out of sunlight. Keep away from children.

---

**8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

---

**Control parameters**

Exposure limits are listed below, if they exist.

**Praziquantel**

None established

**Ivermectin**

None established

**Titanium Dioxide**

ACGIH TLV: 10 mg/m<sup>3</sup> TWA

OSHA PEL: 15 mg/m<sup>3</sup> TWA (Total dust)

**Appropriate engineering controls**

No specific measures necessary. Good general room ventilation is expected to be adequate to control airborne levels.

**Individual protection measures****Respiratory Protection**

Not required under normal conditions of use.

**Skin Protection**

Protective gloves.

---

**8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

---

**Eye/Face Protection**

Not required under normal conditions of use.

**Body Protection**

Normal work wear.

---

**9. PHYSICAL AND CHEMICAL PROPERTIES**

---

**Appearance**

	<b>Physical State</b>	Solid (paste)
	<b>Color</b>	White
<b>Odor</b>		None
<b>Odor Threshold</b>		No data available
<b>pH</b>		Not applicable
<b>Density</b>		No data available
<b>Boiling Range/Point (°C/F)</b>		Not applicable
<b>Melting Point (°C/F)</b>		Not applicable
<b>Flash Point (PMCC) (°C/F)</b>		Not flammable
<b>Vapor Pressure</b>		Not applicable
<b>Evaporation Rate (BuAc=1)</b>		Not applicable
<b>Solubility in Water</b>		No data available
<b>Vapor Density (Air = 1)</b>		Not applicable
<b>VOC</b>		Not applicable
<b>Partition coefficient (n-octanol/water)</b>		Not applicable
<b>Viscosity</b>		Not applicable
<b>Auto-ignition Temperature</b>		No data available
<b>Decomposition Temperature</b>		No data available
<b>Upper explosive limit</b>		No data available
<b>Lower explosive limit</b>		No data available
<b>Flammability (solid, gas)</b>		No data available

---

**10. STABILITY AND REACTIVITY**

---

**Reactivity**

Data is not available

**Chemical Stability**

Stable under normal conditions.

**Possibility of hazardous reactions**

Hazardous polymerization will not occur.

**Conditions to Avoid**

Heat - high temperatures

**Incompatible Materials**

Strong oxidizers

**Hazardous Decomposition Products**

Oxides of carbon – organic compounds

---

**11. TOXICOLOGICAL INFORMATION**

---

See product insert and/or packaging for additional information.

**Acute Toxicity**Ivermectin:

Oral LD50 (rat) 50 mg/kg

Oral LD50 (human) >15mg/kg

Dermal LD50 406 mg/kg (rabbit)

Praziquantel

Oral LD50 (rat) 2840 mg/kg

Dermal LD50 (rat) >2000 mg/kg

**Specific Target Organ Toxicity (STOT) – single exposure**

Ivermectin: At high doses in humans and animals vomiting, tachycardia, blood pressure fluctuation, CNS effects (somnolence, ataxia) and visual disturbances have been observed. Higher doses may cause death due to respiratory depression.

Praziquantel: Acute overexposure (ingestion) may cause dizziness, headache, drowsiness, malaise, abdominal pain.

**Specific Target Organ Toxicity (STOT) – repeat exposure**

Ivermectin: No data available

Praziquantel: Chronic overexposure may cause nausea, lethargy, diarrhea, itching, fever and rash.

**Serious Eye damage/Irritation**

Ivermectin: Slightly irritating to eyes in rabbit tests.

Praziquantel: Not irritating to eyes in rabbit studies.

**Skin Corrosion/Irritation**

Ivermectin: Non-irritating in animal studies.

Praziquantel: Not irritating to skin in rabbit studies.

**Respiratory or Skin Sensitization**

Ivermectin: Hypersensitivity reactions have been reported in humans.

Praziquantel: Not sensitizing to skin in guinea pig study.

**Carcinogenicity**

Titanium Dioxide: IARC Overall Evaluation is 2B (Possibly carcinogenic to humans) IARC evaluation guidelines consider the generation of tumors, in 2 different studies within the same animal species, to be adequate criteria for an assessment of sufficient evidence. The conclusions of several epidemiology studies on more than 20000 TiO<sub>2</sub> industry workers in Europe and the USA did not suggest a carcinogenic effect of TiO<sub>2</sub> dust on the human lung. Mortality from other chronic diseases, including other respiratory diseases, was also not associated with exposure to TiO<sub>2</sub> dust. Based upon these studies, titanium dioxide is not expected to cause lung cancer or chronic respiratory diseases in humans at concentrations experienced in the workplace.

Praziquantel: Long term studies in rats and golden hamsters did not reveal any carcinogenic effect.

**Germ Cell Mutagenicity**

Ivermectin: Negative in the AMES Assay, and in a mouse lymphoma mutation assay. In addition, it did not induce unscheduled DNA synthesis in a human fibroblast cell culture, suggesting that it does not damage DNA.

Praziquantel: Negative results for in vivo and in vitro animal studies.

---

**11. TOXICOLOGICAL INFORMATION**

---

**Reproductive Toxicity**

Ivermectin: Teratogenic in rats, rabbit and mice at or near materno-toxic dose levels. The abnormalities are limited mainly to cleft palate.

Praziquantel: Studies in rats and rabbits have shown no evidence of impaired fertility or harm to the fetus. An increase of the abortion rate was found in rats at three times the single human therapeutic dose.

**Aspiration Hazard**

Not an aspiration hazard.

---

**12. ECOLOGICAL INFORMATION**

---

**Ecotoxicity**

Ivermectin:

LC50 (Trout) 0.003mg/l 96hr

LC50 (Daphnia magna) 0.000025mg/l 48hr

**Mobility in soil**

Ivermectin: Ivermectin is metabolized in the soil. Water solubility is limited and it binds to soil very tightly. It does not bioconcentrate in fish and is not taken up from soil into plants.

**Persistence/Degradability**

Ivermectin: Slow biodegradation. Photodegrades rapidly.

**Bioaccumulative Potential**

No relevant studies identified.

**Other adverse effects**

No relevant studies identified.

---

**13. DISPOSAL CONSIDERATIONS**

---

Dispose of the syringe in an approved landfill or by incineration.

---

**14. TRANSPORT INFORMATION**

---

Contact supplier for transport information.

---

**15. REGULATORY INFORMATION**

---

**United States TSCA Inventory**

This product is not regulated under the US EPA Toxic Substance Control Act.

**Canada DSL Inventory**

All ingredients have not been verified for listing on the Domestic Substance List (DSL).

---

**15. REGULATORY INFORMATION**

---

**California Proposition 65**

This product contains trace amounts of the following chemicals which the State of California has found to cause cancer, birth defects or other reproductive harm: Acetaldehyde

**SARA Title III Sect. 311/312 Categorization**

None

**SARA Title III Sect. 313**

This product does not contain any chemicals listed in Section 313 at or above de minimis concentrations.

---

**16. OTHER INFORMATION**

---

**Legend**

ACGIH: American Conference of Governmental Industrial Hygienists

BOD: Biological Oxygen Demand

CAS#: Chemical Abstracts Service Number

DSL: Domestic Substances List

ECHA: European Chemicals Agency

EPA: Environmental Protection Agency

FIFRA: Federal Insecticide, Fungicide and Rodenticide Act

HDT: Highest Dose Tested

HMIS: Hazardous Materials Identification System IARC: International Agency for Research on Cancer

LC50: Lethal Concentration 50%

LD50: Lethal Dose 50%

LOEL: Lowest Observed Effect Level

N/A: Denotes no applicable information found or available

NFPA: National Fire Protection Association

NOEL: No Observed Effect Level

OSHA: Occupational Safety and Health Administration

PEL: Permissible Exposure Limit

TSCA: Toxic Substances Control Act

SARA: Superfund Amendments and Reauthorization Act

SDS: Safety Data Sheet

STEL: Short Term Exposure Limit

WHMIS: Workplace Hazardous Materials Information System

TLV: Threshold Limit Value

TSCA: Toxic Substance Control Act

Revision Date: December 21, 2015

Replaces: November 9, 2011

Changes made: Updated to GHS Classification.

**Information Source and References**

This SDS is prepared by Hazard Communication Specialists based on information provided by internal company references.

**Prepared By:** EnviroNet LLC.

EQUIMAX is a registered trademark of Virbac S.A.



**SAFETY DATA SHEET**  
**EQUIMAX<sup>®</sup>**  
**(ivermectin 1.87%/praziquantel 14.03%)**  
**Paste**

---

**16. OTHER INFORMATION**

---

The information and recommendations presented in this SDS are based on sources believed to be accurate. Virbac AH, Inc. assumes no liability for the accuracy or completeness of this information. It is the user's responsibility to determine the suitability of the material for their particular purposes. In particular, we make NO WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED, with respect to such information, and we assume no liability resulting from its use. Users should ensure that any use or disposal of the material is in accordance with applicable Federal, State, and local laws and regulations.

---